Coronavirus pandemic: daily updated research and data.
Read more

Our data on COVID-19 vaccinations is updated each morning (London time), with the most recent official numbers up to the previous day.

In our Data Explorer you can see our data on the cumulative number of COVID-19 vaccination doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). You can find charts with the number of people with at least 1 dose, and the number of people fully vaccinated, further down this page.

Open the Data Explorer in a new tab.

Select a group of countries at once: all European countries, 30 largest countries; EU; Americas; OECD.


The Our World in Data COVID vaccination data

To bring this pandemic to an end, a large share of the world needs to be immune to the virus. The safest way to achieve this is with a vaccine. Vaccines are a technology that humanity has often relied on in the past to bring down the death toll of infectious diseases.

Within less than 12 months after the beginning of the COVID-19 pandemic, several research teams rose to the challenge and developed vaccines that protect from SARS-CoV-2, the virus that causes COVID-19.

Now the challenge is to make these vaccines available to people around the world. It will be key that people in all countries — not just in rich countries — receive the required protection. To track this effort we at Our World in Data are building the international COVID-19 vaccination dataset that we make available on this page. It is updated each morning, with the most recent official numbers up to the previous day.

  • Open access: as with all of our data, we are making this dataset openly available, so that everyone can check and use the data that we bring together. You find the vaccination data in our daily-updated repository on GitHub.

Country-by-country data on COVID-19 vaccinations

This page has a number of charts on vaccination. In the box below you can select any country you are interested in — or several, if you want to compare countries.

All charts on this page will then show data for the countries that you selected.

None selected

How many COVID-19 vaccine doses are administered daily?

Daily number of COVID-19 vaccinations administered per 100 people

The following chart shows the daily number of COVID-19 vaccination doses administered per 100 people. This is shown as the rolling seven-day average. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).

Daily number of COVID-19 vaccinations administered

How many COVID-19 vaccination doses have been administered?

The following map and chart show the number of COVID-19 vaccination doses administered per 100 people within a given population. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime as several available COVID vaccines require multiple doses.

Total number of COVID-19 vaccinations administered

The following chart shows the total number of COVID-19 vaccination doses administered. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).

What share of the population has received at least one dose of the COVID-19 vaccine?

The following chart shows the share of the total population that has received at least one dose of the COVID-19 vaccine. This may not equal the share that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

Total number of people who have received at least one dose of the COVID-19 vaccine

The following chart shows the total number of people that have received at least one dose of the COVID-19 vaccine. This may not equal the number that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

What share of the population has been fully vaccinated against COVID-19?

The following chart shows the share of the total population that has been fully vaccinated against COVID-19. This represents the share that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

This data is only available for countries which report the breakdown of doses administered by first and second doses.

Total number of people who have been fully vaccinated against COVID-19

The following chart shows the total number of people that have been fully vaccinated against COVID-19. This represents the number that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

This data is only available for countries which report the breakdown of doses administered by first and second doses.

Which vaccines have been administered in each country?

The following chart shows the cumulative number of doses administered, broken down by vaccine manufacturer.

This is only available for a select number of countries which report the necessary data.

Vaccination policies

This interactive chart maps government policies on COVID-19 vaccination. Note that this only tracks policies on the availability of vaccinations. It does not track the number of people who have been vaccinated.

Countries are grouped into six categories:

  • No availability
  • Availability for ONE of following: key workers/ clinically vulnerable groups / elderly groups
  • Availability for TWO of following: key workers/ clinically vulnerable groups / elderly groups
  • Availability for ALL of following: key workers/ clinically vulnerable groups / elderly groups
  • Availability for all three plus partial additional availability (select broad groups/ages)
  • Universal availability

Vaccination policy data is sourced from the Oxford Coronavirus Government Response Tracker

This data on vaccination policies is sourced from the Oxford Coronavirus Government Response Tracker (OxCGRT).

This resource is published by researchers at the Blavatnik School of Government at the University of Oxford: Thomas Hale, Anna Petherik, Beatriz Kira, Noam Angrist, Toby Phillips and Samuel Webster.

The tracker presents data collected from public sources by a team of over one hundred Oxford University students and staff from every part of the world.

The data presented here is taken directly from the OxCGRT project; Our World in Data do not track policy responses ourselves, and do not make additions to the tracker dataset.

These charts are regularly updated based on the latest version of the response tracker.

OxCGRT is an ongoing collation project of live data. If you see any inaccuracies in the underlying data, or for specific feedback on the analysis or another aspect of the project please contact OxCGRT team. See the tracker’s notes and guidance on data quality.

Attitudes to COVID-19 vaccinations

The Imperial College London YouGov Covid-19 Behaviour Tracker Data Hub gathers global insights on people’s behaviors in response to COVID-19. This survey covers public behaviors and attitudes ranging from mask-wearing to self-isolation, social distancing, symptoms and testing.

The following chart shows monthly data on public willingness to receive the COVID-19 vaccine.

Data represents the share of respondents that agree with the following statement: “If a COVID-19 vaccine were made available to me this week, I would definitely get it.” Respondents were presented with a 1 to 5 scale, ranging from “Strongly agree” (1) to “Strongly disagree” (5). We consider responses of 1 or 2 to be in agreement with the statement.

Vaccine development: vaccines approved for use and in clinical trials

The speed at which the first COVID-19 vaccines were developed was extraordinary. We have previously looked into the history of vaccine development. The measles vaccine was found relatively rapidly: it took only 10 years from the discovery of the pathogen to the development of the first vaccine. But for typhoid it took more than a century, and for some diseases for which we’ve known the pathogens for more than a century (like malaria) we still haven’t found an effective vaccine.

The development of a vaccine against COVID-19 has been much faster than the development of any other vaccine. Within less than a year several successful vaccines have already been announced and were approved for use in some countries. 

The hope is that even more manufacturers develop vaccines for COVID-19. This will be important because eventually a very large share of the world population needs to receive a COVID-19 vaccine.

We are on the way to several vaccines against COVID-19 – vaccine trackers monitor the progress:

Several institutions maintain websites on which they list COVID-19 candidate vaccines that are currently being developed:

Source information country by country

You can download the full dataset alongside the detailed source descriptions on GitHub.

Note that other countries may have also started vaccination campaigns—we’ll add them to our maps and charts as soon as numbers are verifiable based on public official sources.

We do not include participants in the vaccine arm of clinical trials, as this data is not available for many of the hundreds of trials currently taking place.

The population estimates we use to calculate per-capita metrics are all based on the last revision of the United Nations World Population Prospects. The exact values can be viewed in our GitHub repository.

LocationSourceLast observation dateVaccines
AlbaniaMinistry of HealthFebruary 25, 2021Pfizer/BioNTech
AlgeriaMinistry of HealthFebruary 19, 2021Sputnik V
AndorraGovernment of AndorraFebruary 24, 2021Pfizer/BioNTech
AnguillaMinistry of HealthFebruary 14, 2021Oxford/AstraZeneca
ArgentinaMinistry of HealthFebruary 25, 2021Sputnik V
AustraliaGovernment of Australia via covidlive.com.auFebruary 25, 2021Pfizer/BioNTech
AustriaMinistry of HealthFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
AzerbaijanGovernment of AzerbaijanFebruary 6, 2021Oxford/AstraZeneca, Sputnik V
BahrainMinistry of HealthFebruary 25, 2021Pfizer/BioNTech, Sinopharm/Beijing
BangladeshDirectorate General of Health ServicesFebruary 25, 2021Oxford/AstraZeneca
BarbadosMinistry of HealthFebruary 24, 2021Oxford/AstraZeneca
BelarusMinistry of HealthFebruary 18, 2021Sputnik V
BelgiumSciensanoFebruary 24, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
BermudaGovernment of BermudaFebruary 22, 2021Pfizer/BioNTech
BoliviaMinistry of HealthFebruary 11, 2021Sputnik V
BrazilRegional governments via Coronavirus BrasilFebruary 25, 2021Oxford/AstraZeneca, Sinovac
BulgariaMinistry of HealthFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
CambodiaMinistry of HealthFebruary 25, 2021Sinopharm/Beijing
CanadaGovernment of CanadaFebruary 25, 2021Moderna, Pfizer/BioNTech
Cayman IslandsCayman Islands GovernmentFebruary 25, 2021Pfizer/BioNTech
ChileDepartment of Statistics and Health InformationFebruary 25, 2021Pfizer/BioNTech, Sinovac
ChinaNational Health CommissionFebruary 9, 2021Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac
ColombiaMinistry of HealthFebruary 25, 2021Pfizer/BioNTech
Costa RicaNational Health CommissionFebruary 22, 2021Pfizer/BioNTech
CroatiaMinistry of HealthFebruary 25, 2021Pfizer/BioNTech
CyprusGovernment of CyprusFebruary 20, 2021Pfizer/BioNTech
CzechiaMinistry of HealthFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
DenmarkStatens Serum InstitutFebruary 25, 2021Moderna, Pfizer/BioNTech
Dominican RepublicMinistry of Public HealthFebruary 24, 2021Oxford/AstraZeneca
EcuadorGovernment of Ecuador via EcuacovidFebruary 24, 2021Pfizer/BioNTech
EgyptMinistry of HealthJanuary 30, 2021Sinopharm/Beijing
El SalvadorMinistry of HealthFebruary 22, 2021Oxford/AstraZeneca
EnglandGovernment of the United KingdomFebruary 24, 2021Oxford/AstraZeneca, Pfizer/BioNTech
EstoniaNational Health BoardFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Faeroe IslandsGovernment of the Faeroe IslandsFebruary 24, 2021Pfizer/BioNTech
Falkland IslandsGovernment of the Falkland IslandsFebruary 15, 2021Oxford/AstraZeneca
FinlandFinnish Institute for Health and WelfareFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
FrancePublic Health FranceFebruary 24, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
GermanyRobert Koch InstitutFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
GibraltarGovernment of GibraltarFebruary 24, 2021Pfizer/BioNTech
GreeceMinistry of HealthFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
GreenlandGovernment of GreenlandJanuary 27, 2021Pfizer/BioNTech
GuernseyGovernment of GuernseyFebruary 23, 2021Pfizer/BioNTech
GuyanaMinistry of HealthFebruary 22, 2021Oxford/AstraZeneca
HungaryGovernment of HungaryFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
IcelandDirectorate of HealthFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
IndiaMinistry of HealthFebruary 25, 2021Covaxin, Oxford/AstraZeneca
IndonesiaMinistry of HealthFebruary 25, 2021Sinovac
IranGovernment of IranFebruary 17, 2021Sputnik V
IrelandHeath Service ExecutiveFebruary 22, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Isle of ManIsle of Man GovernmentFebruary 25, 2021Oxford/AstraZeneca, Pfizer/BioNTech
IsraelGovernment of IsraelFebruary 25, 2021Moderna, Pfizer/BioNTech
ItalyExtraordinary commissioner for the Covid-19 emergencyFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
JapanMinistry of Health, Labour and WelfareFebruary 25, 2021Pfizer/BioNTech
JerseyGovernment of JerseyFebruary 21, 2021Oxford/AstraZeneca, Pfizer/BioNTech
KuwaitMinistry of HealthFebruary 15, 2021Pfizer/BioNTech
LatviaNational Health ServiceFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
LebanonGovernment of LebanonFebruary 25, 2021Pfizer/BioNTech
LiechtensteinFederal Office of Public HealthFebruary 21, 2021Moderna, Pfizer/BioNTech
LithuaniaMinistry of HealthFebruary 24, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
LuxembourgGovernment of LuxembourgFebruary 24, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
MacaoGovernment of MacaoFebruary 18, 2021Sinopharm/Beijing
MaldivesPresidency of the MaldivesFebruary 25, 2021Oxford/AstraZeneca
MaltaCOVID-19 Malta Public Health Response TeamFebruary 24, 2021Pfizer/BioNTech
MauritiusNational Communication Committee on COVID-19February 17, 2021Oxford/AstraZeneca
MexicoSecretary of HealthFebruary 25, 2021Oxford/AstraZeneca, Pfizer/BioNTech
MonacoNational CouncilJanuary 18, 2021Pfizer/BioNTech
MoroccoMinistry of HealthFebruary 25, 2021Oxford/AstraZeneca, Sinopharm/Beijing
MyanmarMinistry of HealthFebruary 2, 2021Oxford/AstraZeneca
NepalGovernment of NepalFebruary 20, 2021Oxford/AstraZeneca
NetherlandsNational Institute for Public Health and the EnvironmentFebruary 24, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
New ZealandMinistry of HealthFebruary 20, 2021Pfizer/BioNTech
Northern CyprusMinistry of HealthJanuary 22, 2021Pfizer/BioNTech, Sinovac
Northern IrelandGovernment of the United KingdomFebruary 24, 2021Oxford/AstraZeneca, Pfizer/BioNTech
NorwayNorwegian Institute of Public HealthFebruary 24, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
OmanMinistry of HealthFebruary 23, 2021Oxford/AstraZeneca, Pfizer/BioNTech
PakistanNational Command and Operation CentreFebruary 21, 2021Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
PanamaMinistry of HealthFebruary 25, 2021Pfizer/BioNTech
PeruMinistry of HealthFebruary 24, 2021Sinopharm/Beijing
PolandMinistry of HealthFebruary 24, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
PortugalGeneral Directorate of Health via Data Science for Social GoodFebruary 25, 2021Moderna, Pfizer/BioNTech
QatarNational Strategic Group on COVID-19February 18, 2021Pfizer/BioNTech
RomaniaGovernment of RomaniaFebruary 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
RussiaRussian Direct Investment FundFebruary 10, 2021Sputnik V
Saint HelenaGovernment of Saint HelenaFebruary 3, 2021Oxford/AstraZeneca
Saudi ArabiaSaudi Health CouncilFebruary 24, 2021Pfizer/BioNTech
ScotlandGovernment of the United KingdomFebruary 24, 2021Oxford/AstraZeneca, Pfizer/BioNTech
SenegalMinistry of HealthFebruary 24, 2021Sinopharm/Beijing
SerbiaGovernment of SerbiaFebruary 25, 2021Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
SeychellesExtended Programme for ImmunisationFebruary 23, 2021Oxford/AstraZeneca, Sinopharm/Beijing
SingaporeMinistry of HealthFebruary 18, 2021Pfizer/BioNTech
SlovakiaMinistry of HealthFebruary 25, 2021Pfizer/BioNTech
SloveniaNational Institute of Public Health, via SledilnikFebruary 24, 2021Oxford/AstraZeneca, Pfizer/BioNTech
South AfricaMinistry of HealthFebruary 25, 2021Johnson&Johnson
SpainMinistry of HealthFebruary 24, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Sri LankaMinistry of HealthFebruary 24, 2021Oxford/AstraZeneca
SwedenPublic Health Agency of SwedenFebruary 25, 2021Oxford/AstraZeneca, Pfizer/BioNTech
SwitzerlandFederal Office of Public HealthFebruary 21, 2021Moderna, Pfizer/BioNTech
Trinidad and TobagoMinistry of HealthFebruary 22, 2021Oxford/AstraZeneca
TurkeyCOVID-19 Vaccine Information PlatformFebruary 25, 2021Sinovac
Turks and Caicos IslandsMinistry of HealthFebruary 8, 2021Pfizer/BioNTech
UkraineMinistry of HealthFebruary 25, 2021Oxford/AstraZeneca
United Arab EmiratesNational Emergency Crisis and Disaster Management AuthorityFebruary 25, 2021Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V
United KingdomGovernment of the United KingdomFebruary 24, 2021Oxford/AstraZeneca, Pfizer/BioNTech
United StatesCenters for Disease Control and PreventionFebruary 25, 2021Moderna, Pfizer/BioNTech
WalesGovernment of the United KingdomFebruary 24, 2021Oxford/AstraZeneca, Pfizer/BioNTech
ZimbabweMinistry of HealthFebruary 25, 2021Sinopharm/Beijing

Sign up for regular updates from Our World in Data


→ If you want to keep up-to-date with on our work on COVID-19, and the many other topics we cover you can sign up to our newsletter.